Annovis Bio’s Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients
June 11, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for...
Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast
June 05, 2024 08:00 ET
|
Annovis Bio, Inc.
MALVERN, Pa., June 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies...
Annovis Bio Announces First Quarter 2023 Financial Results and Provides Corporate Update
May 11, 2023 07:00 ET
|
Annovis Bio, Inc.
BERWYN, Pa., May 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced...
Annovis Bio Announces Issuance of U.S. Patent Covering the Use of Lead Drug Candidate, Buntanetap, for Prevention or Treatment of Disease States Due to Metal Dis-Homeostasis in Healthy or Sick Humans
April 27, 2023 07:00 ET
|
Annovis Bio, Inc.
BERWYN, Pa., April 27, 2023 (GLOBE NEWSWIRE) -- (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company developing treatments for neurodegenerative diseases announced today...
Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit
March 11, 2021 07:05 ET
|
Annovis Bio, Inc.
BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...
Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
January 31, 2020 11:46 ET
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE American: ANVS), a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative...
Annovis Bio Announces Pricing of Initial Public Offering
January 28, 2020 23:31 ET
|
Annovis Bio, Inc.
BERWYN, Pa., Jan. 28, 2020 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a clinical stage, drug platform company addressing Alzheimer's, Parkinson's and other neurodegenerative diseases today announced the...
Annovis Appoints Jeffrey McGroarty Chief Financial Officer
July 09, 2019 08:45 ET
|
Annovis Bio, Inc.
BERWYN, Pa., July 09, 2019 (GLOBE NEWSWIRE) -- Annovis Bio, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...
QR Pharma Adopts new Corporate Name: Annovis Bio
June 24, 2019 13:30 ET
|
Annovis Bio, Inc.
BERWYN, Pa., June 24, 2019 (GLOBE NEWSWIRE) -- QR Pharma, Inc., a biopharmaceutical company developing novel therapies for the treatment of Alzheimer’s, Parkinson’s and other neurodegenerative...